medigraphic.com
ISSN 3061-8142 (Electronic)
ISSN 0484-7903 (Print)

2004, Number S1

<< Back Next >>

Rev Mex Anest 2004; 27 (S1)

New advances in receptor pharmacology

Schwinn DA, Duke JB

Language: English
References: 19
Page: 83-87
PDF size: 96.47 Kb.


Text Extraction

Objective: The goal of this review is to give the clinician a broad perspective on recent updates in cardiovascular pharmacology. Specifically, this review discusses new drugs, old drugs used in new ways, and a glimpse into the future of cardiovascular pharmacogenetics.


REFERENCES

  1. 1— Berkowitz DE. Cellular signal transduction. Scientific Principles of Anesthesia. Edited by D.A. Schwinn. Volume: 2, Current Medicine, Philadelphia, 1998.

  2. 2— Choi DJ, Rockman HA. Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. Cell Biochem Biophys 1999;31:321-329.

  3. 3— Eckhart AD, Koch WJ. Transgenic studies of cardiac adrenergic receptor regulation. J Pharmacol Exp Ther 2001;299:1-5.

  4. 4— Hamm HE. The many faces of G protein signaling. J Biol Chem 1998;273:669-72.

  5. 5— Holloway JW, Dunbar PR, Riley GA, Sawyer GM, Fitzharris PF, Pearce N, Le Gros GS, Beasley R. Association of beta2-adrenergic receptor polymorphisms with severe asthma. Clin Exp Allergy 2000;30:1097-1103.

  6. 6— Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997;49:369-379.

  7. 7— Landry Y, Gies JP. Heterotrimeric G proteins control diverse pathways of transmembrane signaling, a base for drug discovery. Mini Rev Med Chem 2002;2:361-372.

  8. 8— Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. New Engl J Med 1996;335:1713-1720.

  9. 9— Nanavaty U, Goldstein AD, Levine SJ. Polymorphisms in candidate asthma genes. Am J Med Sci 2001;321:11-16.

  10. 10— Podlowski S, Wenzel K, Luterh HP, Muller J, Bramlage P, Baumann G, Felix SB, Speer A, Hetzer R, Kopke K, Hoehe MR, Wallukat G. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000;78:87-93.

  11. 11— Perry SJ, Lefkowitz RJ. Arresting developments in heptahelical receptor signaling and regulation. Trends Cell Biol 2002;12:130-138.

  12. 12— Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-650.

  13. 13— Rathz DA, Gregory KN, Fang Y, Brown KM, Liggett SB. Hierarchy of polymorphic variation and desensitization permutations relative to beta-1 and beta-2 adrenergic signaling. J Biol Chem 2003;278:10784-10789.

  14. 14— Rockman HA, Koch WJ, Lefkowitz RJ. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol 1997;272:H1553-9.

  15. 15— Royster RL. Perioperative beta-blockade can reduce morbidity and mortality. Anesthesia Patient Safety Foundation Newsletter 2002;17(2):21-23.

  16. 16— Skiba NP, Hamm HE. How Gsa activates adenylyl cyclase. Nat Struct Biol 1998;5:88-92.

  17. 17— Smiley RM, Kwatra MM, Schwinn DA. New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. J Cardiothorac Vasc Anesth 1998;12:80-95.

  18. 18— Wagoner LE, Craft LL, Singh B, Suresh DP, Zengel PW, McGuire N, Abraham WT, Chenier TC, Dorn GW, Liggett SB. Polymorphisms of the beta(2)-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000;86:834-840.

  19. 19— Weinshilboum R. Inheritance and drug response. N Engl J Med 2003;348:529-537.




2020     |     www.medigraphic.com